CD11b, CD19, CD22, CD33, CD34, CD45, CD56, CD79b, HLA-DR, TdT
This tube is designed to assess surface CD22 and nuclear TdT expression among presumed abnormal B-lymphoblastic cell populations. It includes antibodies to surface CD45, CD11b, CD22, CD19, CD34, CD33, CD79b, CD56, and HLA-DR, as well as a cytoplasmic TdT antibody.
Disease State: Precursor B-Lymphoblastic Lymphoma/Leukemia (B-ALL)
CPT Code(s): 88185x10 (reference only; CPTs may vary)
Turnaround Time: Physician will be contacted by 9:00 PM PST the day of receipt for acute/life threatening conditions; next business day for routine flow cases.
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR -
• Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR -
• Tissue: Finely minced tissue in RPMI transport media - OR -
• Body fluids: In RPMI transport media